ATE279517T1 - Il-17 receptor - Google Patents

Il-17 receptor

Info

Publication number
ATE279517T1
ATE279517T1 AT96912451T AT96912451T ATE279517T1 AT E279517 T1 ATE279517 T1 AT E279517T1 AT 96912451 T AT96912451 T AT 96912451T AT 96912451 T AT96912451 T AT 96912451T AT E279517 T1 ATE279517 T1 AT E279517T1
Authority
AT
Austria
Prior art keywords
receptors
receptor
isolated
ctla
inhibit
Prior art date
Application number
AT96912451T
Other languages
English (en)
Inventor
Zhengbin Yao
Melanie K Spriggs
William C Fanslow
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27021039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE279517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE279517T1 publication Critical patent/ATE279517T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96912451T 1995-03-23 1996-03-21 Il-17 receptor ATE279517T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41053595A 1995-03-23 1995-03-23
US53876595A 1995-08-07 1995-08-07
PCT/US1996/004018 WO1996029408A1 (en) 1995-03-23 1996-03-21 Il-17 receptor

Publications (1)

Publication Number Publication Date
ATE279517T1 true ATE279517T1 (de) 2004-10-15

Family

ID=27021039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912451T ATE279517T1 (de) 1995-03-23 1996-03-21 Il-17 receptor

Country Status (15)

Country Link
US (9) US5869286A (de)
EP (1) EP0817847B2 (de)
JP (1) JP4373495B2 (de)
KR (1) KR100467998B1 (de)
AT (1) ATE279517T1 (de)
AU (1) AU696775B2 (de)
CA (1) CA2215394C (de)
DE (1) DE69633617T3 (de)
DK (1) DK0817847T4 (de)
ES (1) ES2229264T5 (de)
MX (1) MX9707021A (de)
NO (1) NO974258L (de)
NZ (1) NZ306653A (de)
PT (1) PT817847E (de)
WO (1) WO1996029408A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
DE69634726T2 (de) * 1995-07-19 2006-05-04 Genetics Institute, LLC, Cambridge Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US7005412B1 (en) * 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
WO1998023284A1 (en) * 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
ES2333385T3 (es) * 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
CA2316364A1 (en) * 1997-12-22 1999-07-01 Kjell-Morten Myhr Method for disease prognosis based on fc receptor genotyping
WO1999035263A2 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
CN1367688A (zh) * 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
AU4369000A (en) * 1999-04-26 2000-11-10 Duke University Inhibition of complement action
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
DK1897945T3 (da) * 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
ES2380812T3 (es) * 1999-12-23 2012-05-18 Genentech, Inc. Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1266002A2 (de) * 2000-03-16 2002-12-18 Amgen Inc., Il-17 rezeptor ähnliche moleküle und verwendungen davon
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030092881A1 (en) * 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271860A1 (en) * 2000-07-06 2002-01-21 Zymogenetics Inc. Murine cytokine receptor
WO2002008259A2 (en) * 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
WO2002038764A2 (en) * 2000-11-10 2002-05-16 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
EP2322200A3 (de) * 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und Methoden für die Behandlung von immune verwandte Krankheiten
JP4441170B2 (ja) * 2002-11-28 2010-03-31 独立行政法人理化学研究所 Ｓ１２リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法
DK1670511T3 (da) * 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
EP1765083A4 (de) * 2004-05-28 2008-08-20 Serono Lab Verwendung von il-17 bei der behandlung von fruchtbarkeitsstörungen
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006034278A2 (en) * 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
JP4590249B2 (ja) * 2004-11-17 2010-12-01 独立行政法人理化学研究所 糖タンパク質合成用の無細胞タンパク質合成システム
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
JP4787488B2 (ja) * 2004-11-19 2011-10-05 独立行政法人理化学研究所 直鎖状鋳型ｄｎａを用いた無細胞タンパク質合成方法及びそのための細胞抽出液
GT200600065A (es) * 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CN101160528A (zh) * 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
WO2007149814A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
FR2910324B1 (fr) * 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US7790676B2 (en) * 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
EP2144928A2 (de) * 2007-04-20 2010-01-20 Amgen Inc. Identifikation und verfahren zur anwendung der preligandenassemblydomäne des il-17-rezeptors
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
EP2203476B1 (de) * 2007-09-25 2016-10-26 Genzyme Corporation Zusammensetzungen und verfahren zur inhibierung von interleukinpfaden
JP5704677B2 (ja) * 2007-11-05 2015-04-22 独立行政法人理化学研究所 膜タンパク質の製造方法
WO2009136976A2 (en) * 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX360946B (es) * 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2809660B1 (de) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur il-17-modulierung
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CA3032514C (en) 2015-07-31 2021-05-04 Takehiro SHINODA Method of producing membrane protein and utilization thereof
EP3452598A4 (de) 2016-05-06 2020-04-29 Exicure, Inc. Konstrukte aus liposomaler sphärischer nukleinsäure (sna) mit antisense-oligonukleotiden (aso) zum spezifischen knockdown von interleukin-17-rezeptor-mrna
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
CN114107385A (zh) 2019-01-17 2022-03-01 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
EP4028053A1 (de) 2019-09-11 2022-07-20 Bausch Health Ireland Limited Verfahren zur behandlung von nicht-alkoholischer fettleberkrankheit (nafld) mit il-17ra-antikörper
JP2022176672A (ja) * 2021-05-17 2022-11-30 国立大学法人北海道大学 ペプチド及び医薬用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1998023284A1 (en) * 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists

Also Published As

Publication number Publication date
JPH11503309A (ja) 1999-03-26
EP0817847A1 (de) 1998-01-14
MX9707021A (es) 1997-11-29
US5869286A (en) 1999-02-09
US6072033A (en) 2000-06-06
AU696775B2 (en) 1998-09-17
PT817847E (pt) 2005-02-28
EP0817847B1 (de) 2004-10-13
US6191104B1 (en) 2001-02-20
ES2229264T3 (es) 2005-04-16
DK0817847T3 (da) 2005-02-14
KR100467998B1 (ko) 2005-11-25
CA2215394C (en) 2011-04-26
CA2215394A1 (en) 1996-09-26
NO974258D0 (no) 1997-09-15
AU5526396A (en) 1996-10-08
DK0817847T4 (da) 2009-10-05
US6096305A (en) 2000-08-01
US20090068737A1 (en) 2009-03-12
ES2229264T5 (es) 2009-12-17
NZ306653A (en) 1999-03-29
US6100235A (en) 2000-08-08
JP4373495B2 (ja) 2009-11-25
US6197525B1 (en) 2001-03-06
US6072037A (en) 2000-06-06
US20100233186A1 (en) 2010-09-16
EP0817847B2 (de) 2009-09-09
KR19980703061A (ko) 1998-09-05
DE69633617T3 (de) 2010-05-20
DE69633617D1 (de) 2004-11-18
DE69633617T2 (de) 2005-11-03
WO1996029408A1 (en) 1996-09-26
NO974258L (no) 1997-11-24

Similar Documents

Publication Publication Date Title
ATE279517T1 (de) Il-17 receptor
LU91758I9 (de)
ATE360032T1 (de) Cystein-reiche rezeptoren-train
FI972945L (fi) Antigeenien antamiseen soveltuvia koostumuksia
DZ2026A1 (fr) Compositions vaccinantes.
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
EP0837927A4 (de) Monoklonale affen-antikörper gegen humane b7.1 und/oder b7.2 antigene, primatisierte derivate und pharmazeutische zusammensetzungen
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
NO20055446L (no) Anvendelse av et interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandlingav kronisk reumatoid artritt
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
ITRM920476A0 (it) Formulazioni galeniche contenenti ciclosporina.
DE69226431D1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
EP0589386A3 (de) Fluorosilikon-Kautschuk-Zusammensetzungen.
FI893643L (fi) Farmaceutiska kompositioner.
DE69007908D1 (de) Shampoo-Zusammensetzung.
FI910088L (fi) Oral farmaceutisk komposition.
BG100248A (bg) Инхибитори на скваленсинтетаза
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817847

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0817847

Country of ref document: EP